Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C] CT1812 in Healthy Men
NCT05225389Phase 1Completed
- Sponsor
- Cognition Therapeutics, Inc.
- Start
- Dec 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zervimesine in Alzheimer's disease (AD), sponsored by Cognition Therapeutics, Inc. Primary endpoints: Plasma CT1812 Concentration at 96 Hours Timepoint, Plasma M6/CP199 Concentration at 144 Hours Timepoint and 8 more. Started Dec 2021; status: completed.
02
Drugs
zervimesine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05225389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05225389.